Remove 2015 Remove Clinical Trials Remove Conditions Remove Events
article thumbnail

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Cannabis Law Report

NYSE: AMAM), a position he previously held from 2010 through 2015. I am so very proud of all Anebulo has achieved over the past 18 months, including building out a highly effective team, securing new intellectual property protection, preparing and starting a proof-of-concept clinical trial, advancing regulatory discussions with the U.S.

article thumbnail

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need. It is estimated that, in 2015, 3% of people in the UK were living with PTSD. Corine de Boer, M.D.,

Therapy 52
article thumbnail

Jones Day: The life sciences regulatory regime in Australia

Cannabis Law Report

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. We also used manifest textual analysis to search for word frequencies, and specific conditions referred to in the articles retrieved. Spasticity from neurological conditions. Background. Conclusions. Bonini et al.

article thumbnail

NO BRAINER: CBD AND THC FOR HEAD INJURIES

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”.

THC 64
article thumbnail

Green Relief - Untitled Article

Green Relief

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. These plant cannabinoids were also deemed useful for treating other neurodegenerative conditions, “such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”.